RFG Advisory’s Altimmune ALT Stock Holding History

RFG Advisory’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-324,397	Closed	-$1.62M	–	922
2025 Q1	$1.62M	Buy	+324,397	New	+$2.05M	0.04%	308

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RFG Advisory's ALT Position: Q2 2025 in Review

RFG Advisory sold out of Altimmune (ALT) in Q2 2025, closing a stake of 324,397 shares — an estimated $1.62M sold.

RFG Advisory first reported a position in ALT in Q1 2025 and held it in 1 quarter. The position peaked at $1.62M in Q1 2025. 180 funds tracked by Wall St. Rank hold ALT as of Q2 2025.

RFG Advisory reported no remaining Altimmune position as of Q2 2025 after selling out during the quarter.
RFG Advisory sold 324,397 Altimmune shares in Q2 2025, an estimated $1.62M.
RFG Advisory first reported a position in Altimmune in Q1 2025 and held it in 1 quarter.
RFG Advisory's Altimmune position peaked at $1.62M in Q1 2025.
180 funds tracked by Wall St. Rank held Altimmune as of Q2 2025.

Based on RFG Advisory's 13F filing for Q2 2025, filed 28 Jul 2025.